| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IXICO Aktie jetzt für 0€ handeln | |||||
| Do | IXICO validates automated brain imaging analysis platform | 1 | Investing.com | ||
| Do | IXICO: Automatisierte Analyseplattform für Gehirnbilder übertrifft manuelle Verfahren | 1 | Investing.com Deutsch | ||
| Do | IXICO plc - Validation of Neuroimaging Technology Platform | - | RNS | ||
| 12.02. | IXICO secures £1.5 million contract extension for Huntington's trial | 13 | Investing.com | ||
| 12.02. | IXICO sichert sich Vertragsverlängerung über 1,5 Millionen Pfund für Huntington-Studie | 13 | Investing.com Deutsch | ||
| 12.02. | IXICO plc - Correction: c.£1.5 million Contract Extension | 12 | RNS | ||
| 12.02. | IXICO plc - c.£1.5 million Contract Extension | 12 | RNS | ||
| 05.02. | IXICO plc - Appointment of Chief Commercial Officer | 12 | RNS | ||
| 23.01. | IXICO shareholders approve all resolutions at annual meeting | 13 | Investing.com | ||
| 23.01. | IXICO plc - Results of AGM | 13 | RNS | ||
| 09.12.25 | IXICO plc - Share option award | 12 | RNS | ||
| 09.12.25 | IXICO plc - Financial Results for year ended 30 September 2025 | 12 | RNS | ||
| 01.12.25 | Ixico strengthens scientific advisory board with two appointments | 13 | Sharecast | ||
| 01.12.25 | IXICO plc - Operational Update | 13 | RNS | ||
| 27.11.25 | IXICO to release full year 2025 results on December 9 | 13 | Investing.com | ||
| 27.11.25 | IXICO veröffentlicht Jahresergebnisse 2025 am 9. Dezember | 13 | Investing.com Deutsch | ||
| 27.11.25 | IXICO plc - Notice of 2025 Full Year Results and IMC | 12 | RNS | ||
| 17.11.25 | Ixico wins GBP3.7 million deal to support Huntington's Disease trial | 13 | Alliance News | ||
| 17.11.25 | AIM WINNERS & LOSERS: OptiBiotix and Ixico rise on deal wins | 14 | Alliance News | ||
| 17.11.25 | IXICO plc - Clinical Trial Contract Win | 12 | RNS |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 31,320 | -2,64 % | Eli Lilly und Novo Nordisk: Angst vor einem Preiskrieg bringt Aktien unter Druck | Novo Nordisk will ab 2027 die Preise für seine Blockbuster-Medikamente Wegovy und Ozempic in den USA drastisch senken und setzt damit Wettbewerber Eli Lilly unter Zugzwang. Die Aktien der beiden Pharmakonzerne... ► Artikel lesen | |
| AURORA CANNABIS | 3,105 | -2,66 % | Is Aurora Cannabis Stock Ready to 10X in the Next Pot Boom? | ||
| CANOPY GROWTH | 0,914 | -1,61 % | Is It Time to Dump Your Shares of Canopy Growth?? | ||
| TILRAY BRANDS | 6,400 | -1,69 % | MDMA-Herausforderer Bioxyne punktet mit 112% Umsatzplus. Und was macht Tilray? | ||
| VERTEX PHARMACEUTICALS | 414,65 | -0,30 % | Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $1.191 billion... ► Artikel lesen | |
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | TAAT Global Alternatives Inc (2): TAAT Global CEO Saxon resigns | ||
| MPH HEALTH CARE | 22,000 | +1,38 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
21.11.2025 / 12:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| CRONOS GROUP | 2,240 | -0,62 % | Cronos Group Inc.: Cronos Group Reports 2025 Fourth Quarter and Full-Year Results | Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025... ► Artikel lesen | |
| SYNBIOTIC | 2,315 | -0,86 % | EQS-News: SYNBIOTIC SE: Globale Dynamik im Cannabismarkt: Neue Signale aus den USA stärken langfristige Perspektiven für Europa und SYNBIOTIC | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Marktbericht/Sonstiges
Globale Dynamik im Cannabismarkt: Neue Signale aus den USA stärken langfristige Perspektiven für Europa und SYNBIOTIC... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | -33,33 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| EYEPOINT | 15,100 | -2,58 % | EyePoint, Inc.: EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema | - Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets - - Topline data for DURAVYU in DME anticipated in 2H 2027 - WATERTOWN, Mass.... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,180 | +3,51 % | Organigram Global Inc: Organigram launches Edison, Boxhot in Australia | ||
| GREEN THUMB INDUSTRIES | 5,335 | -1,57 % | Green Thumb Industries Reports Fourth Quarter and Full Year 2025 Results | CHICAGO and VANCOUVER, British Columbia, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| SNDL | 1,291 | -0,23 % | 1CM Inc.: SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan | Edmonton, Alberta and Toronto, Ontario--(Newsfile Corp. - January 7, 2026) - SNDL Inc. (NASDAQ: SNDL) (CSE: SNDL) ("SNDL") and 1CM Inc. (CSE: EPIC) (OTCQB: MILFF) (FSE: IQ70) ("1CM") are pleased... ► Artikel lesen | |
| SINOPHARM | 2,282 | -2,48 % | HSI Closes at 26,765, Up 175 pts; HSTI Closes at 5,260, Down 10 pts; HAIDILAO Up over 6%; HSBC HOLDINGS, TINGYI, SINOPHARM, TIME INTERCON, WANGUO GOLD GP Hit New Highs; Market Turnover Rises |